[HTML][HTML] Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide
RS Mehta, RM Saliba, S Ghanem, AM Alousi… - … and Cellular Therapy, 2022 - Elsevier
With the use of post-transplantation cyclophosphamide (PTCy), the outcomes of mismatched
related donor hematopoietic cell transplantation (HCT) are now approaching those of …
related donor hematopoietic cell transplantation (HCT) are now approaching those of …
[HTML][HTML] Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a …
The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease
(GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in …
(GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in …
[HTML][HTML] Single antigen–mismatched unrelated hematopoietic stem cell transplantation using high-dose post-transplantation cyclophosphamide is a suitable …
AS Jorge, M Suárez-Lledó, A Pereira… - Biology of Blood and …, 2018 - Elsevier
The optimal prophylaxis regimen for graft-versus-host disease (GVHD) in the setting of
mismatched unrelated donor (MMUD) allogeneic hematopoietic stem cell transplantation …
mismatched unrelated donor (MMUD) allogeneic hematopoietic stem cell transplantation …
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes
R Devillier, S Bramanti, S Fürst, B Sarina… - Bone Marrow …, 2016 - nature.com
Unmanipulated haploidentical transplantation (Haplo-SCT) using post-transplantation
cyclophosphamide (PT-Cy) represents an alternative for patients with high-risk diseases …
cyclophosphamide (PT-Cy) represents an alternative for patients with high-risk diseases …
Posttransplant cyclophosphamide beyond haploidentical transplantation
LJ Arcuri, AAF Ribeiro, N Hamerschlak… - Annals of Hematology, 2024 - Springer
Posttransplant cyclophosphamide (PTCy) has practically revolutionized haploidentical
(Haplo) hematopoietic cell transplantation (HCT). Comparisons between Haplo with PTCy …
(Haplo) hematopoietic cell transplantation (HCT). Comparisons between Haplo with PTCy …
[HTML][HTML] Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: a systematic review …
LJ Arcuri, MTM Aguiar, AAF Ribeiro… - Biology of Blood and …, 2019 - Elsevier
Hematopoietic stem cell transplantation (HSCT) is the standard treatment for patients with
high-risk hematologic malignancies. Only approximately 25% of siblings are HLA-matched …
high-risk hematologic malignancies. Only approximately 25% of siblings are HLA-matched …
Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: mechanisms and results
H Elmariah, EJ Fuchs - Seminars in hematology, 2019 - Elsevier
Allogeneic blood or marrow transplantation (BMT) is a curative therapy for a number of high-
risk hematologic malignancies. Historically, only patients with a human leukocyte antigen …
risk hematologic malignancies. Historically, only patients with a human leukocyte antigen …
[HTML][HTML] Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide
A Im, A Rashidi, T Wang, M Hemmer… - Biology of blood and …, 2020 - Elsevier
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of
haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD) …
haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD) …
Haploidentical vs. mismatched unrelated donor transplants with posttransplant cyclophosphamide-based GVHD prophylaxis
Post-transplant cyclophosphamide (PTcy) has yielded encouraging results as GVHD
prophylaxis in haploidentical transplants [1-3]. Given its encouraging activity, PTcy is being …
prophylaxis in haploidentical transplants [1-3]. Given its encouraging activity, PTcy is being …
[HTML][HTML] The benefits of the post-transplant cyclophosphamide in both haploidentical and mismatched unrelated donor setting in allogeneic stem cells transplantation
J Dybko, M Sobczyk-Kruszelnicka, S Makuch… - International Journal of …, 2023 - mdpi.com
Allogeneic hematopoietic cell transplantation (alloHSCT) is a standard therapeutic approach
for acute leukemias and many other hematologic malignancies. The proper choice of …
for acute leukemias and many other hematologic malignancies. The proper choice of …